Drug Profile
Infliximab biosimilar - Reliance Life Sciences
Alternative Names: BOW-015; Infimab; R-TPR-015Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator EPIRUS Biopharmaceuticals
- Developer EPIRUS Biopharmaceuticals; Reliance Life Sciences; Sun Pharmaceutical Industries
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- Marketed Plaque psoriasis; Rheumatoid arthritis
- No development reported Autoimmune disorders
Most Recent Events
- 01 Sep 2019 Launched for Plaque psoriasis in India (unspecified route), before September 2019
- 01 Aug 2019 Registered for Plaque psoriasis in India (unspecified route), before August 2019
- 14 Mar 2019 No recent reports of development identified for preregistration for Autoimmune disorders in Malaysia, Indonesia, Indonesia, Thailand (IV)